Search research articles
Contact Us
Filters
Showing results (191-200 of 277) with videos related to
Page
of 28
Sort By:
Cancer Research Communications
|
December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2014
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors
Philippe L Bedard, Josep Tabernero, Filip Janku, et al.
Molecular Cancer Therapeutics
|
October 5, 2013
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
Prasanth Ganesan, Filip Janku, Aung Naing, et al.
Journal for Immunotherapy of Cancer
|
April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Matthew J Reilley, Ann Bailey, Vivek Subbiah, et al.
JCO Precision Oncology
|
October 31, 2017
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study
Apostolia-Maria Tsimberidou, David S Hong, Yang Ye, et al.
Investigational New Drugs
|
April 28, 2021
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Kyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Cancer Immunology Research
|
September 21, 2022
Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies
Filip Janku, Sae-Won Han, Toshihiko Doi, et al.
The Oncologist
|
March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials
Ryan W Huey, Goldy C George, Penny Phillips, et al.
Cancer Research
|
May 20, 2016
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Jennifer J Wheler, Filip Janku, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2020
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors
Alexej Ballhausen, Jennifer J Wheler, Daniel D Karp, et al.
Page
of 28
Search research articles
Search
Showing results (191-200 of 277) with videos related to
Sort By:
Page
of 28
Cancer Research Communications
|
December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2014
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors
Philippe L Bedard, Josep Tabernero, Filip Janku, et al.
Molecular Cancer Therapeutics
|
October 5, 2013
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
Prasanth Ganesan, Filip Janku, Aung Naing, et al.
Journal for Immunotherapy of Cancer
|
April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Matthew J Reilley, Ann Bailey, Vivek Subbiah, et al.
JCO Precision Oncology
|
October 31, 2017
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study
Apostolia-Maria Tsimberidou, David S Hong, Yang Ye, et al.
Investigational New Drugs
|
April 28, 2021
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Kyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Cancer Immunology Research
|
September 21, 2022
Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies
Filip Janku, Sae-Won Han, Toshihiko Doi, et al.
The Oncologist
|
March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials
Ryan W Huey, Goldy C George, Penny Phillips, et al.
Cancer Research
|
May 20, 2016
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Jennifer J Wheler, Filip Janku, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2020
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors
Alexej Ballhausen, Jennifer J Wheler, Daniel D Karp, et al.
Page
of 28